Tumor-infiltrating lymphocyte (TIL) have been recognized as a novel biomarker, besides other FDA-approved markers, because the action mechanism of ICI relies on anti-tumor immunity of TILs by inhibiting the immune checkpoints of the tumor, and the clinical outcome of ICI has correlations with PD-L1 expression and TIL across different tumor types [14,15,16,17]. This evidence concerns the gene CD274 and neoplasm.